Literature DB >> 6368587

Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion.

D C Robbins, S E Shoelson, A H Rubenstein, H S Tager.   

Abstract

Familial hyperproinsulinemia, a hereditary syndrome in which individuals secrete high amounts of 9,000-mol wt proinsulin-like material, has been identified in two unrelated cohorts. Separate analysis of the material from each of the two cohorts had suggested that the proinsulin-like peptide was a conversion intermediate in which the C-peptide remained attached to the insulin B-chain in one case, whereas it was a conversion intermediate in which the C-peptide remained attached to the insulin A-chain in the other. To reinvestigate this apparent discrepancy, we have now used chemical, biochemical, immunochemical, and physical techniques to compare in parallel the structures of the immunoaffinity chromatography-purified, proinsulin-like peptides isolated from the serum of members of both families. Our results show that affected individuals in both cohorts secrete two-chained intermediates of proinsulin conversion in which the COOH-terminus of the C-peptide is extended by the insulin A-chain and from which the insulin B-chain is released by oxidative sulfitolysis. Analysis of the conversion intermediates by reverse-phase high-performance liquid chromatography using two different buffer systems showed that the proinsulin-related peptides from both families elute at a single position very near that of the normal intermediate des-Arg31, Arg32-proinsulin. Further, treatment of these peptides with acetic anhydride prevented trypsin-catalyzed cleavage of the C-peptide from the insulin A-chain, a result demonstrating the presence of Lys64 and the absence of Arg65 in both abnormal forms. We conclude that individuals from both cohorts with familial hyperproinsulinemia secret very similar or identical intermediates of proinsulin conversion in which the C-peptide remains attached to the insulin A chain and in which Arg65 has been replaced by another amino acid residue.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368587      PMCID: PMC425073          DOI: 10.1172/JCI111264

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Biological activity of proinsulin and related polypeptides in the fat tissue.

Authors:  S S Yu; A E Kitbachi
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

2.  Isolation and characterization of proinsulin C-peptide from bovine pancreas.

Authors:  D F Steiner; S Cho; P E Oyer; S Terris; J D Peterson; A H Rubenstein
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

3.  A circulating variant of human proalbumin.

Authors:  S O Brennan; R W Carrell
Journal:  Nature       Date:  1978-08-31       Impact factor: 49.962

4.  Familial hyperproinsulinemia: partial characterization of circulating proinsulin-like material.

Authors:  K H Gabbay; R M Bergenstal; J Wolff; M E Mako; A H Rubenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

5.  Studies on the nature of antigenicity of A and B chains of bovine insulin.

Authors:  P T Varandani
Journal:  Biochemistry       Date:  1967-01       Impact factor: 3.162

6.  Familial hyperproinsulinemia. An autosomal dominant defect.

Authors:  K H Gabbay; K DeLuca; J N Fisher; M E Mako; A H Rubenstein
Journal:  N Engl J Med       Date:  1976-04-22       Impact factor: 91.245

7.  Determination of free and total insulin and C-peptide in insulin-treated diabetics.

Authors:  H Kuzuya; P M Blix; D L Horwitz; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

8.  Diabetes due to secretion of an abnormal insulin.

Authors:  B D Given; M E Mako; H S Tager; D Baldwin; J Markese; A H Rubenstein; J Olefsky; M Kobayashi; O Kolterman; R Poucher
Journal:  N Engl J Med       Date:  1980-01-17       Impact factor: 91.245

9.  A structurally abnormal insulin causing human diabetes.

Authors:  H Tager; B Given; D Baldwin; M Mako; J Markese; A Rubenstein; J Olefsky; M Kobayashi; O Kolterman; R Poucher
Journal:  Nature       Date:  1979-09-13       Impact factor: 49.962

10.  Characterization of seven C-peptide antisera.

Authors:  O K Faber; C Binder; J Markussen; L G Heding; V K Naithani; H Kuzuya; P Blix; D L Horwitz; A H Rubenstein
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

View more
  12 in total

1.  Partial diversion of a mutant proinsulin (B10 aspartic acid) from the regulated to the constitutive secretory pathway in transfected AtT-20 cells.

Authors:  D J Gross; P A Halban; C R Kahn; G C Weir; L Villa-Komaroff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

2.  Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism.

Authors:  A Arnold; S A Horst; T J Gardella; H Baba; M A Levine; H M Kronenberg
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

3.  A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway.

Authors:  R J Carroll; R E Hammer; S J Chan; H H Swift; A H Rubenstein; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Posttranslational cleavage of proinsulin is blocked by a point mutation in familial hyperproinsulinemia.

Authors:  Y Shibasaki; T Kawakami; Y Kanazawa; Y Akanuma; F Takaku
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

5.  A superactive insulin: [B10-aspartic acid]insulin(human).

Authors:  G P Schwartz; G T Burke; P G Katsoyannis
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

6.  A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia.

Authors:  S J Chan; S Seino; P A Gruppuso; R Schwartz; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Biochemical and clinical implications of proinsulin conversion intermediates.

Authors:  B D Given; R M Cohen; S E Shoelson; B H Frank; A H Rubenstein; H S Tager
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Scintigraphic distribution of 123 I labelled proinsulin, split conversion intermediates and insulin in rats.

Authors:  F Sodoyez-Goffaux; J C Sodoyez; M Koch; C J De Vos; B H Frank
Journal:  Diabetologia       Date:  1988-11       Impact factor: 10.122

9.  The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin.

Authors:  M Maislos; P M Mead; D H Gaynor; D C Robbins
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

10.  Differential rates of conversion of rat proinsulins I and II. Evidence for slow cleavage at the B-chain/C-peptide junction of proinsulin II.

Authors:  S V Sizonenko; P A Halban
Journal:  Biochem J       Date:  1991-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.